Acelyrin stock plunges after positive Phase II data readout in thyroid eye disease
Acelyrin plans to initiate two Phase III studies this quarter, which will enrol up to 350 patients with thyroid eye disease (TED).
Acelyrin plans to initiate two Phase III studies this quarter, which will enrol up to 350 patients with thyroid eye disease (TED).
What's Your Reaction?
